Skip to content
Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Get the podcast

Jonathan Kolitz JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute For patients with acute myeloid leukemia in first remission, new data suggests tha

The Audio Journal of Oncology
Jonathan Kolitz

Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NYGEORGE CANELLOS, Dana-Farber Cancer InstituteFor patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial fromJonathan Kolitzof Monter Cancer Center, Lake Success, NY, whileGeorge Canellosof the Dana-Farber Cancer Institute provided comment.

Tags

acutecancerleukemiamyeloidNewspatientpodcastpodcastingreportreportstrial

Next in ASH 2007

All 11 interviews

Interview 9 of 11

New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni

9 December 2007

Related Episodes

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min